Skip to content. | Skip to navigation

Personal tools

Spencer D. Martin, PhD.

Postdoctoral Fellow

Spencer2017   675 West 10th Avenue, Vancouver, B.C., V5Z 1L3, Canada 

BCCA | BCCRC | Integrative Oncology | Cancer Genetics | Wan Lam Lab | Spencer Martin

Education and Previous Training

  • 2016: PhD. Interdisciplinary Oncology, University of British Columbia 

  • 2010: BSc. (honours) Microbiology, University of Victoria

Research Interests

  • Cancer immunotherapy, lung cancer, ovarian cancer, cancer genomics, T cell therapy, neoantigens

Scholarships & Awards

  • 2012: CIHR-CGS Doctoral award
  • 2011: CIHR-CGS Masters award
  • 2011: Four Year Fellowship, University of British Columbia


  • SD Martin, DA Wick, JS Nielsen, N Little, RA Holt, BH Nelson, A library based screening method identifies neoantigen-reactive T cells in the peripheral blood prior to relapse of ovarian cancer. 2017 OncoImmunology, e1371895
  • JS Nielsen, AR Chang, DA Wick, CG Sedgwick, Z Zong, AJ Mungall, SD Martin, NN Kinloch, S Ott-Langer, ZL Brumme, SP Treon, JM Connors, RD Gascoyne, JR Webb, BR Berry, RD Morin, N Macpherson, BH Nelson, Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. Oncoimmunology. 2017 Apr 28;6(7):e1321184. 
  • SD Martin, Identifying and targeting immunogenic mutations in ovarian cancer. University of British Columbia. PhD Dissertation, 2016 June.
  • JS Nielsen, SD Martin, BH Nelson, Personalized immunotherapy targeting the cancer mutanome. Encyclopeida of Immunobiology 2016 4 (doi: 10.1016/B978-0-12-374279-7.1), 426 - 433
  • SD Martin, SD Brown, DA Wick, JS Nielsen, DR Kroeger, K Twumasi-Boateng, RA Holt, BH Nelson, Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines. PLoS One.2016 May 18;11(5):e0155189
  • SD Martin, G Coukos, RA Holt, BH Nelson, Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era. Annals of Oncology, 2015 Dec;26(12):2367-74. 
  • SD Brown, RL Warren, EA Gibb, SD Martin, JJ Spinelli, BH Nelson, RA Holt, Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Research, 2014 May;24(5):743-50.
  • ML McKinnon, J Rozmus, SY Fung, AF Hirshfeld, KL Del Bel, L Thomas, N Marr, SD Martin, AK Marwaha, JJ Priatel, R Tan, C Senger, A Tsang, J Prendiville, AK Junker, M Seear, KR Schultz, LM Sly, RA Holt, MS Patel, JM Friedman, SE Turvey, Combined immunodeficiency associated with homozygous MALT1 mutations. Journal of Allergy and Clinical Immunology. 2014 May;133(5):1458-62.
  • DA Wick, JR Webb, JS Nielsen, SD Martin, DR Kroeger, K Milne, M Castellarin, K Twumasi-Boateng, PH Watson, RA Holt, BH Nelson, Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clinical Cancer Research. 2014 Mar 1;20(5):1125-34.
  • NR West, SE Kost, SD Martin, K Milne, RJ Deleeuw, BH Nelson, PH Watson. Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. British Journal of Cancer. 2013 Jan 15;108(1):155-62.
  • DA Wick, SD Martin, BH Nelson, JR Webb. Profound CD8+ T cell immunity elicited by sequential daily immunization with exogenous antigen plus the TLR3 agonist poly(I:). Vaccine. 2011 Jan 29;29(5):984-93.

Selected Invited Talks and Lectures


Abstracts and Presentations



BCCA | BCCRC | Integrative Oncology | Cancer Genetics | Wan Lam Lab | Spencer Martin